AVD-104

近日资讯 Recent News▼ 中国接触镜安全监控会议召开，眼舒康新型润眼液受关注 图片来源：家长里短小论坛 12月13日中国接触镜安全监控委员会年度会议在南昌举行，眼舒康几丁糖功能性润眼液携15mL多剂量无防腐剂新包装亮相。专家指出该润眼液含有的几丁糖成分可改善角膜荧光素染色评分，加快眼表损伤修复，新包装采用法国进口阻菌瓶，通过三重阻菌系统保障无菌，兼顾安全性与便利性，即将正式上市。 信息来源：家长里短小论坛 深圳欧科健完成3000万美元B轮融资，助推双抗眼科新药中美II期临床 图片来源：中华网财经 专注眼科创新药研发的深圳欧科健生物医药宣布完成3000万美元B轮融资，由知名产业投资机构与启明创投联合领投，博裕万物跟投，现有股东LongRiver江远投资、博远资本持续加码。所募资金将重点推进核心产品OCUL101的中美 II 期临床试验，该药物为全球首创双特异性抗体，针对新生血管性年龄相关性黄斑变性、糖尿病性黄斑水肿、地图样萎缩三大致盲性眼底病，采用抗VEGF-补体C5双靶点设计，可同时阻断血管新生、渗漏及炎症反应。公司计划2026年1月启动国内首个生物药用于地图样萎缩的II期临床，同步推进中美两地研究，有望填补全球相关治疗空白。 信息来源：中华网财经 普瑞眼科启动第六代ICL晶体技术，多地分院成首批临床合作单位 普瑞眼科集团在南昌召开EVO+ICL (V5)项目启动研讨会，正式推出第六代ICL晶体植入技术。该技术光学区扩展至6.1mm，暗瞳覆盖值达7.6mm，可降低术后眩光风险，适配夜间高频用眼人群。昆明润城普瑞眼科医院跻身首批临床合作医院，上海、合肥等地多家普瑞眼科分院获首批临床应用合作中心授牌，多地患者将同步享受该全球领先近视矫正技术。 信息来源：昆明信息港 Aviceda Therapeutics眼科新药IIb期试验显示对地图样萎缩有抑制效果 图片来源：Aviceda Therapeutics Aviceda Therapeutics公司公布了其药物AVD-104针对地图样萎缩的IIb期临床试验结果。尽管在主要终点上，该药物与每月使用的阿伐西普相比，在地图样萎缩区域变化率方面无统计学差异，但12个月的试验数据显示，与安慰剂组和自然病程组相比，AVD-104能使地图样萎缩病灶的生长速度降低约31%，展现出一定的疾病控制潜力。 信息来源：Ophthalmology Times 艾吉泰康终止甲状腺眼病新药3期临床试验 图片来源：Argenx Argenx（艾吉泰康）公司宣布终止Efgartigimod SC用于治疗甲状腺眼病的3期UP LIGHTED临床试验。此次终止是基于独立数据监测委员会的建议，理由是该试验被判定为“无效”，意味着该药物在该适应症的研发中未能达到预期的临床效果，后续将不再推进相关试验进程。 信息来源：Ophthalmology Times 如有意向合作，请联系我们： chinasight@fudan-innovcenter.com 新伙伴专属礼遇！首次合作即享双重福利： 1. 免费稿件发布名额 1 次 2. 独家深度专访 1 篇 *具体条件与需求请咨询工作人员，所有内容须经审核后方可发布。 声明 本文相关生物医药及眼科领域产业新闻内容，由AI工具辅助完成网络信息搜集与整理工作。内容整理过程中已对信息来源及准确性进行核查，但AI生成内容可能存在疏漏，敬请谅解。本文仅传递产业资讯，不提供医疗、投资建议。鉴于互联网的开放性和文章创作的复杂性，我们无法保证所转载的所有文章均已获得原作者的明确授权。如果您是原作者或拥有相关权益，请与我们联系，我们将立即删除未经授权的文章。 本声明旨在保障信息透明度，AI工具仅为辅助手段，不享有相关内容的著作权及署名权。

Despite the fail, Aviceda still plans to test its lead asset in two sham-controlled phase 3 trials in 2026.\n Aviceda Therapeutics has hit a snag in its goal to deliver a new treatment for geographic atrophy (GA), an advanced form of dry age-related macular degeneration. The biotech’s lead asset, AVD-104, failed to beat Astellas’ Izervay (avacincaptad pegol) at slowing the rate of retina lesion growth, missing the primary endpoint of a phase 2 trial.The trial enrolled 300 patients with GA and treated them with monthly eye injections of either Izervay or AVD-104 at low or high doses.\"The study did not meet its primary endpoint, which was designed to assess non-inferiority,\" a company spokesperson told Fierce Biotech. \"No statistical differences in GA lesion growth rates were observed across the three study arms.\"AVD-104 led to no serious adverse events, Aviceda reported in a Dec. 15 release, with the most common side effect being eye floaters. AVD-104 is a nanoparticle adorned with polysialic acid, designed to bind to receptors on the surfaces of overactive immune cells like macrophages that cause eye inflammation in GA.Though it failed to top Izervay, AVD-104 did reduce the growth rate of GA lesions by 31% compared to previously published sham-treatment rates from Izervay’s phase 3 trial, according to Aviceda. The company described this finding as “clinically meaningful.” In addition, the company highlighted that patients given AVD-104 were able to read an average of 0.6 more letters in a visual acuity test after 12 months of treatment.“These results reinforce our belief that AVD-104 can provide meaningful functional vision benefit while reducing lesion progression, and has the potential to become a differentiated therapy addressing a significant unmet medical need for patients living with GA,” Aviceda CEO Jeffrey Nau, Ph.D., said in the release. Despite the failure, which Aviceda attributed to “imbalances in key baseline lesion characteristics across treatment arms,” the company still plans to test its lead asset in two sham-controlled phase 3 trials in 2026, according to the release. The Massachusetts-based biotech closed a $207.5 million series C in January to support its phase 3 vision.Aviceda was also testing the nanoparticle in a phase 2 trial for diabetic macular edema, but halted the study early due to “insufficient study drug supply and study funding constraints,” according to the clinicaltrials.gov database.GA has been a tough indication for pharma to crack. Roche blockbuster hopeful lampalizumab flopped in a critical phase 3 trial in 2017, with the Swiss pharma subsequently ditching the asset. Novartis scrapped its own GA candidate, acquired from Gyroscope Therapeutics, in September 2023 because of weak data.And in September 2024, Alkeus Pharmaceuticals reported that its oral candidate failed to reduce GA lesion growth in a phase 3 trial, with the company nevertheless declaring the results “clinically meaningful.”Apellis\' Syfovre (pegcetacoplan) was the first GA drug to break through, securing FDA approval in February 2023. However, the med was flagged by the agency for rare cases of severe eye inflammation that can lead to blindness just months later. Astellas picked up Izervay through the $5.9 billion acquisition of Iveric Bio in March 2023, garnering an approval of its own that August.Neither Izervay nor Syfovre is able to restore vision, and injections of both come with the risk of side effects like inflammation, bleeding and blurred sight.Outside of therapeutics, Science Corp. announced in October that its retinal implant was able to give GA patients some vision back in a clinical trial.Editor\'s note: This story was updated at 4:00 p.m. ET with a statement from Aviceda.